YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YIHCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $6 | $4 | $1 |
| % Growth | -40.8% | 68.1% | 309.8% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | $3 | $5 | $3 | $0 |
| % Margin | 75% | 79.2% | 76% | 52.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $1 | $2 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $1 |
| Operating Income | $1 | $2 | $0 | -$0 |
| % Margin | 18.1% | 37.4% | 8.6% | -50.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $1 | $2 | $0 | -$1 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | $0 | $2 | $0 | -$1 |
| % Margin | 13% | 31.7% | 2% | -64.3% |
| EPS | 0.55 | 2.26 | 0.087 | -0.67 |
| % Growth | -75.7% | 2,494.7% | 113% | – |
| EPS Diluted | 0.55 | 2.26 | 0.087 | -0.67 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $3 | $1 | -$0 |
| % Margin | 28.7% | 43.6% | 18.5% | -22.6% |